Poland· PL-100486986

Aquipta

A atogepant product containing atogepantum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 16 of our 19 countries.

ATC N02CD07

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAquiptaATCN02CD07REGISTER NO.PL-100486986PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Atogepant is registered in 16 of 19 countries.

Countries holding a registration under ATC N02CD07 (atogepant), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 11 of them publish a price we can compare per daily dose

Atogepant · ATC N02CD07

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of atogepant costs, country by country.

Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Atogepant · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • IT Italy$96.51
  • CH Switzerland$95.15
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Atogepantum
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Country
Poland (PL)
ATC code
N02CD07
ATC class
Atogepant
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    08054083026114

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Atogepant in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atogepant products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Aquipta
  • Iceland · Aquipta
  • Liechtenstein · Aquipta
  • Norway · Aquipta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2fa56b32-b485-4051-89a7-58a45bcec18b
GET /v1/drugs/2fa56b32-b485-4051-89a7-58a45bcec18b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "10 mg",
  "packaging": "08054083026114 ¦ Rp ¦ EU/1/23/1750/001 ¦ 151060\n28 tabl.\nRp ¦ EU/1/23/1750/002 ¦ 151061\n98 tabl.",
  "substance": "Atogepantum 10 mg",
  "common_name": "Atogepantum",
  "pl_product_id": "100486986",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about atogepant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.